Andrx, Amphastar Pen Deal For Generic Lovenox

Law360, New York (May 5, 2005, 12:00 AM EDT) -- Drug maker Andrx Corp. has entered into a marketing rights agreement with Amphastar Pharmaceuticals for a generic version of Sanofi-Aventis’ Lovenox, a treatment for deep vein thrombosis.

Amphastar's generic version is currently the subject of a patent infringement lawsuit brought by Aventis and is under a 30-month stay that expires in February 2006.

In December, Aventis’ bid for a reissuance of the U.S. patent for best-selling anti-blood clotting drug Lovenox finally won approval from the U.S. Patent and Trademark office.

The USPTO previously rejected two attempts...
To view the full article, register now.